Alzheimer's Research
Alzheimer's Research
A once-fringe theory is gaining traction: common viruses like herpes may help trigger the brain changes behind Alzheimer's disease. Here's what scientists actually know so far.
Nearly 6 million Americans live with Alzheimer's disease today, and that number is projected to more than double by 2050. Despite decades of research, there is still no cure and no way to reliably stop its progression. That's why a once-marginal idea is getting fresh attention from major research institutions: that common infections, particularly herpes viruses, might help set the disease in motion. Harvard neurobiologist Robert Moir and researchers at the Alzheimer's Association are examining whether amyloid-beta, the sticky protein long blamed for Alzheimer's, actually serves a protective purpose against microbes, and whether that protective response sometimes goes wrong. This isn't a definitive answer, but it's reshaping how scientists think about prevention and treatment.
Harvard researchers found that herpes viruses can trigger amyloid-beta buildup in the brain, the same protein linked to Alzheimer's. Antiviral treatment may lower dementia risk, but experts say it's too early to draw firm conclusions.
For decades, amyloid-beta protein has been Alzheimer's prime suspect. As the disease progresses, this protein builds up and clumps into hardened plaques that disrupt brain function, leading to memory loss and other symptoms. What has puzzled scientists is why the buildup happens in the first place, and amyloid-beta has often been dismissed as biological junk with no real purpose.
Harvard neurobiologist Robert Moir, an assistant professor of neurology at Harvard Medical School and Massachusetts General Hospital, disagrees with that dismissal. He points out that the same amyloid-beta found in human brains has existed largely unchanged for roughly 450 million years, and appears across most vertebrates, including reptiles, birds, and fish. For something so ancient to persist that long, he argues, it almost certainly serves a biological function worth investigating.
The notion that infection could be connected to Alzheimer's isn't new. Rebecca Edelmayer, PhD, director of scientific engagement at the Alzheimer's Association, notes that scientists are actively trying to pin down whether common infections contribute to the disease's development. Moir explains that the infection theory has circulated for more than a century, but lost momentum in the 1980s once researchers shifted focus almost entirely to amyloid-beta plaques.
That earlier shift meant the infection angle got sidelined for years, pursued by only a small number of researchers, and not all of them specialists in brain disease. Now, new laboratory findings are reviving the question and prompting a broader group of scientists to take another look at what triggers plaque formation in the first place.
Moir's research team proposes that amyloid-beta functions as part of the brain's immune defense. When a microbe enters the brain, amyloid-beta fibers reportedly wrap around the invader, forming a ball of plaque that neutralizes it. Moir describes the effect bluntly: the microbe becomes forever trapped inside the plaque, which is why he insists amyloid-beta is not functionless.
This reframes plaques not as accidental damage but as a defensive response gone awry. If that's accurate, the buildup associated with Alzheimer's could represent an overactive or chronic version of a normally protective process, one triggered repeatedly by infections the brain is trying to contain.
| Pathogen Studied | Suspected Link | Research Status |
|---|---|---|
| HSV1 (oral herpes) | Triggered amyloid plaques in mice and human brain cells | Active, published in Neuron |
| HSV2 (genital herpes) | Found in Alzheimer's-affected brain regions | Early-stage |
| Chlamydia pneumoniae | Detected in some Alzheimer's brains | Suggestive, needs more study |
| Spirochete bacteria (Lyme, syphilis) | Proposed trigger for plaque formation | Suggestive, needs more study |
Moir and colleagues tested this idea using two common forms of herpes in a study published in the journal Neuron. Injecting mice with herpes virus triggered the development of amyloid plaques, and the same effect occurred in human brain cells studied in the lab. A separate research team, publishing in the same issue, found several types of herpes virus present in brain regions affected by Alzheimer's.
That second study also found the viruses appeared to influence the behavior of genes linked to amyloid-beta production. Together, the two papers offered some of the strongest experimental evidence yet that a specific, extremely common virus could play a role in triggering the plaque-forming process central to Alzheimer's disease.
The World Health Organization estimates that roughly two-thirds of the world's population carries HSV1, the herpes strain Moir studied, and the second strain he examined is even more widespread. Once someone is infected, the virus stays for life. That raises an obvious question: if herpes is so common, why doesn't everyone develop Alzheimer's?
Moir suggests the virus usually stays dormant and causes no symptoms. He speculates that a combination of factors, such as age and genetics, may reactivate it and trigger an inflammatory immune response in the brain. He floats the possibility that a genetic mutation could prevent inflammation from switching off once it starts, allowing damage to accumulate over time.
Taiwanese researchers tracked outcomes over a 10-year period and found that HSV1 infection more than doubled a person's risk of developing dementia. Notably, people with herpes who received antiviral medication had roughly the same dementia risk as people who had never been infected at all, a striking finding that suggests treatment might matter.
Still, the study's authors caution it is too soon to say whether treating herpes could genuinely lower a person's chances of developing Alzheimer's. Correlation isn't causation, and more controlled research is needed before antivirals could be considered any kind of preventive strategy for dementia.
In 2016, an international group of scientists published a joint statement in the Journal of Alzheimer's Disease calling for expanded research into infection's role in the disease. They cited earlier studies pointing to possible ties with chlamydia, a sexually transmitted infection, as well as fungal infections and spirochetes, the type of bacteria responsible for Lyme disease and syphilis.
The statement noted that herpes itself was first investigated in this context nearly 30 years earlier, underscoring just how long this line of inquiry has existed on the margins of mainstream Alzheimer's research, even as evidence has slowly accumulated across multiple suspected pathogens.
None of this research changes how families should approach a loved one's memory loss today. There is no approved antiviral protocol for preventing Alzheimer's, and the infection theory remains one hypothesis among several competing on how the disease develops. Diagnosis, symptom management, and safety planning still depend on standard medical evaluation.
What the research does offer is hope that new treatment angles, focused on inflammation and infection rather than amyloid alone, could eventually open doors that current therapies haven't. For now, families dealing with a dementia diagnosis benefit most from connecting with knowledgeable local resources who understand memory care options and can help evaluate the right level of support as needs change.
Emerging research suggests common viruses like herpes may help trigger the amyloid-beta buildup seen in Alzheimer's, but scientists stress this is one theory among several, not a proven cause or a basis for treatment yet.
The idea that infections like herpes could contribute to Alzheimer's disease has moved from the fringes of research toward genuine scientific interest, thanks to studies showing that viruses can trigger amyloid-beta buildup in both mice and human brain cells. Researchers like Robert Moir believe amyloid-beta may function as a defense mechanism against microbes rather than a byproduct of disease. Still, with roughly two-thirds of the world's population carrying HSV1 and only a fraction developing Alzheimer's, infection alone clearly isn't the whole story. Age, genetics, and inflammation likely all play a role. For families navigating a loved one's cognitive changes today, the practical guidance hasn't changed: get a proper medical evaluation and connect with senior care advisors who understand memory care and local resources.
If a loved one shows sudden confusion, rapid memory decline, difficulty recognizing familiar people, or trouble managing daily tasks they previously handled easily, don't wait to see if it passes. Schedule a medical evaluation promptly, since early diagnosis opens up more treatment and planning options, and sudden severe confusion can also signal an urgent, treatable medical issue.